Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

BACKGROUND Mutations in the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) play a critical role in cancer cell growth and resistance to therapy. Most mutations occur at codons 12 and 13. In colorectal cancer, the presence of any mutant KRas amino acid substitution is a negative predictor of patient response to targeted therapy. However, in non-small cell lung cancer (NSCLC), the evidence that KRAS mutation is a predictive factor is conflicting. METHODS We used data from a molecularly targeted clinical trial for 215 patients with tissues available out of 268 evaluable patients with refractory NSCLC to examine associations between specific mutant KRas proteins and progression-free survival and tumor gene expression. Transcriptome microarray studies of patient tumor samples and reverse-phase protein array studies of a panel of 67 NSCLC cell lines with known substitutions in KRas and in immortalized human bronchial epithelial cells stably expressing different mutant KRas proteins were used to investigate signaling pathway activation. Molecular modeling was used to study the conformations of wild-type and mutant KRas proteins. Kaplan-Meier curves and Cox regression were used to analyze survival data. All statistical tests were two-sided. RESULTS Patients whose tumors had either mutant KRas-Gly12Cys or mutant KRas-Gly12Val had worse progression-free survival compared with patients whose tumors had other mutant KRas proteins or wild-type KRas (P = .046, median survival = 1.84 months) compared with all other mutant KRas (median survival = 3.35 months) or wild-type KRas (median survival = 1.95 months). NSCLC cell lines with mutant KRas-Gly12Asp had activated phosphatidylinositol 3-kinase (PI-3-K) and mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) signaling, whereas those with mutant KRas-Gly12Cys or mutant KRas-Gly12Val had activated Ral signaling and decreased growth factor-dependent Akt activation. Molecular modeling studies showed that different conformations imposed by mutant KRas may lead to altered association with downstream signaling transducers. CONCLUSIONS Not all mutant KRas proteins affect patient survival or downstream signaling in a similar way. The heterogeneous behavior of mutant KRas proteins implies that therapeutic interventions may need to take into account the specific mutant KRas expressed by the tumor.

[1]  C. Der,et al.  Distinct requirements for Ras oncogenesis in human versus mouse cells. , 2002, Genes & development.

[2]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[3]  J Andrew McCammon,et al.  Mapping the nucleotide and isoform-dependent structural and dynamical features of Ras proteins. , 2008, Structure.

[4]  Phillip T. Hawkins,et al.  Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ , 2000, Cell.

[5]  Zhiping Weng,et al.  ZRANK: Reranking protein docking predictions with an optimized energy function , 2007, Proteins.

[6]  W. Gerald,et al.  A Genome-Wide Screen for Promoter Methylation in Lung Cancer Identifies Novel Methylation Markers for Multiple Malignancies , 2006, PLoS medicine.

[7]  P. Hawkins,et al.  Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. , 2000, Cell.

[8]  E. Fontham,et al.  Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  M Broggini,et al.  Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  R. DePinho,et al.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. , 2004, Cancer cell.

[11]  G. Capellá,et al.  Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. , 1991, Environmental health perspectives.

[12]  J. Tichelaar,et al.  Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model. , 2005, Carcinogenesis.

[13]  A. Norman,et al.  Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. , 1998, Journal of the National Cancer Institute.

[14]  Eric Deutsch,et al.  Are RAS mutations predictive markers of resistance to standard chemotherapy? , 2009, Nature Reviews Clinical Oncology.

[15]  N. Malats,et al.  Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes. , 2009, Mutation research.

[16]  J. Bertino,et al.  K-ras modulates the cell cycle via both positive and negative regulatory pathways , 1997, Oncogene.

[17]  O. Kranenburg,et al.  The KRAS oncogene: past, present, and future. , 2005, Biochimica et biophysica acta.

[18]  Lan Huang,et al.  Three-dimensional structure of the Ras-interacting domain of RalGDS , 1997, Nature Structural Biology.

[19]  J. Downward,et al.  SnapShot: Ras Signaling , 2008, Cell.

[20]  R. D'Agostino,et al.  Effects of mutant human Ki-ras(G12C) gene dosage on murine lung tumorigenesis and signaling to its downstream effectors. , 2008, Toxicology and applied pharmacology.

[21]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[22]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[23]  Lan Huang,et al.  Structural basis for the interaction of Ras with RaIGDS , 1998, Nature Structural Biology.

[24]  M. Barbacid,et al.  Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival , 2010, The EMBO journal.

[25]  Amedeo Caflisch,et al.  Wordom: a program for efficient analysis of molecular dynamics simulations , 2007, Bioinform..

[26]  Marshall W. Anderson,et al.  EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. , 2007, Cancer research.

[27]  Laura A. Sullivan,et al.  Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. , 2010, Cancer research.

[28]  J. Siegfried,et al.  Prognostic value of specific KRAS mutations in lung adenocarcinomas. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[29]  A. Tee,et al.  Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. , 2009, Cellular signalling.

[30]  J. Minna,et al.  Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. , 2006, Cancer research.

[31]  M. Raponi,et al.  KRAS mutations predict response to EGFR inhibitors. , 2008, Current opinion in pharmacology.